Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Siegfried Holding AG: Initiation of Research Coverage

    William Blair initiated research coverage of Siegfried Holding AG (SFZN-SWX CHF 85.00), a global contract development and manufacturing organization (CDMO) focused on small molecule drug substance manufacturing and drug product manufacturing across a variety of dosage forms. Siegfried is based in Zofingen, Switzerland.

    Read more

  • Avoid the Most Common Mistakes in Estate Planning

    Estate planning is all about your legacy. A well-planned estate plan is one that meets your goals and avoids unnecessary costs, delays, and conflicts.

    Read more

  • Cash-Flow Planning for Retirement

    A five-step guide to generating retirement income efficiently and effectively.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures